Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells

Journal of Pharmacological Sciences

Volumn 111, Issue 1, 2009, Pages 1-12

  Byung, Chul Park ^a   Thapa, Dinesh ^a   Jong, Suk Lee ^a   Park, Su Young ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

Author keywords

Angiogenesis; Extracellular signal regulated kinase (ERK); Matrix metalloproteinase (MMP); Reactive oxygen species (ROS); Troglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4,4' ISOPROPYLIDENEDIPHENOL; ACETYLCYSTEINE; DIPHENYLIODONIUM SALT; GELATINASE A; MATRIGEL; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD 98056; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; REACTIVE OXYGEN METABOLITE; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CELL INVASION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NONHUMAN; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; CHROMANS; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349506372     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08305FP     Document Type: Article

References (54)

1. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Söhndel S, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996;271:29461-29467. (Pubitemid 26382666)
2. Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis. 2003;6:165-169. (Pubitemid 38506661)
3. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;2001:RE21.
4. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272:32521-32527. (Pubitemid 28011938)
5. Ushio-Fukai M, Tang Y, Fukai T, Dikalov S, Ma Y, Fujimoto M, et al. Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160-1167. (Pubitemid 36076365)
6. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Dikalov SI, Chen YE, Tojo T, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ Res. 2004;95:276-283. (Pubitemid 39056288)
7. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37-S43. (Pubitemid 33001442)
8. Johnsen M, Lund LR, Rømer J, Almholt K, Danø K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998;10:667-671. (Pubitemid 28477027)
9. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein /extracellular signal-related kinase activation and cell migration. Cancer Res. 2004;64:1044-1049. (Pubitemid 38176908)
10. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503. (Pubitemid 24379627)
11. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cerebral Blood Flow Metab. 1998; 18:1163-1172.
12. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. Iumb Life. 2001;52:61-66. (Pubitemid 33769671)
13. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001;20:4782-4793. (Pubitemid 32848631)
14. Kim KH, Cho YS, Park JM, Yoon SO, Kim KW, Chung AS. Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett. 2007;581:3303-3310.
15. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92:80-86.
16. Takada I, Suzawa M, Kato S. Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor γ and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci. 2005;97:184-189. (Pubitemid 40410257)
17. Gralinski MR, Rowse PE, Breider MA. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J Cardiovasc Pharmacol. 1998;31: 909-913. (Pubitemid 28265301)
18. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension. 2002;40:748-754. (Pubitemid 35278614)
19. Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, et al. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol. 2005;56:400-408. (Pubitemid 41095403)
20. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103. (Pubitemid 28533518)
21. Game BA, Xu M, Lopes-virella MF, Huang Y. Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones. Atherosclerosis. 2003;169:235-243. (Pubitemid 37297469)
22. Yoshimoto K, Nishizawa S, Koshino H, Sato Y, Teramae N, Maeda M. Assignment of hydrogen-bond structure in a ligandnucleobase complex inside duplex DNA: combined use of quantum chemical calculations and 15N NMR experiments. Nucleic Acids Symp Ser (Oxf). 2005;49:255-256.
23. Kim MS, Lee EJ, Kim HR. Moon A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 2003; 63:5454-5461.
24. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem. 1986;261: 2814-2818. (Pubitemid 17218296)
25. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
27. Maeyama K, Emi M, Tachibana M. Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor γ in mast cells: its roles in proliferation and differentiation. J Pharmacol Sci.2005;97:190-194. (Pubitemid 40410258)
28. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891-1895. (Pubitemid 34219737)
29. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-367. (Pubitemid 32662214)
30. Konturek PC, Kania J, Kukharsky V, Raithel M, Ocker M, Rembiasz K, et al. Implication of peroxisome proliferator-activated receptor γ and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J Pharmacol Sci. 2004;96:134-143. (Pubitemid 39469604)
31. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274:9116-9121. (Pubitemid 29164719)
32. Murata T, Hata Y, Kim S, Hsueh WA, Law RE, Hinton DR. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001;119:709-717. (Pubitemid 32417377)
33. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska- Kiec A. Ligands of peroxisome proliferatoractivated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and inmacrophages. Acta Biochimica Polonica. 2000;47:1147-1157.
34. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2000;271:571-574. (Pubitemid 30444669)
35. Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res. 2007;74:140-150. (Pubitemid 46366953)
36. Chu K, Lee ST, Koo JS, Jung KH, Kim EH, Sinn DI, et al. Peroxisome proliferatoractivated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 2006;1093:208-218. (Pubitemid 43946402)
37. Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B. β-Carotene induces apoptosis and up-regulates peroxisome proliferatoractivated receptor γ expression and reactive oxygen species production in MCF-7 cancer cells. Eur J Cancer. 2007;43:2590-2601. (Pubitemid 350086930)
38. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ. Peroxisome proliferator-activated receptor β-mediated upregulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 2008;68:2912-2919. (Pubitemid 351556291)
39. Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer. 2007;43:1755-1763. (Pubitemid 47042376)
40. 2. J Biol Chem. 1999;274:17042-17048.
41. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPAR-γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110: 923-932.
42. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Aterioscler Thromb Vasc Biol. 1999;19:546-551. (Pubitemid 29135154)
43. Ikeda S, Ushio-Fukai M, Zuo L, Tojo T, Dikalov S, Patrushev NA, et al. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2005;96: 467-475. (Pubitemid 40354541)
44. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev NA, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111:2347-2355. (Pubitemid 40647071)
45. Kang DW, Choi CH, Park JY, Kang SK, Kim YK. Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells. Neurochem Res. 2008;33:551-561.
46. Jung JY, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. Role of mitogen-activated protein kinase (MAPK) in troglitazoneinduced osteoblastic cell death. Toxicology. 2007;234:73-82. (Pubitemid 46517825)
47. Kim HJ, Woo IS, Kang ES, Eun SY, Kim GH, Ham SA, et al. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells. Biochem Biophys Res Commun. 2006;349:660-667.
48. Guo W, Xie W, Han J. Modulation of adipocyte lipogenesis by octanoate: involvement of reactive oxygen species. Nutr Metab (Lond). 2006;3:30.
49. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430-435. (Pubitemid 30694801)
50. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an antiinflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312. (Pubitemid 32323021)
51. Jung JY, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. Role of mitogen-activated protein kinase (MAPK) in troglitazoneinduced osteoblastic cell death. Toxicology. 2007;234:73-82. (Pubitemid 46517825)
52. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1- MMP). J Biol Chem. 1998;273:1216-1222. (Pubitemid 28049224)
53. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci. 2005;118:2325-2340.
54. Sheu WH, Ou HC, Chou FP, Lin TM, Yang CH. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci. 2006;78:1520-1528.